Enzymotec (ENZY) Misses Q4 EPS by 13c

Enzymotec (NASDAQ: ENZY) reported Q4 EPS of ($0.10), $0.13 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $10.6 million versus the consensus estimate of $11.47 million.

For earnings history and earnings-related data on Enzymotec (ENZY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business
• Home Depot beats estimates, reaffirms fiscal 2026 guidance